The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

mTOR Signaling in Growth Control and Disease

Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · see citing works

<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works

Lanthanum Chloride Inhibits LPS Mediated Expressions of Pro-Inflammatory Cytokines and Adhesion Molecules in HUVECs: Involvement of NF-κB-Jmjd3 Signaling

Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,759 · see citing works

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154 · see citing works

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,974 · see citing works

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · see citing works

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · see citing works

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665 · see citing works

Recurring mutations found by sequencing an acute myeloid leukemia genome

Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · see citing works

Histone demethylation by a family of JmjC domain-containing proteins

Tsukada, Y.-I., Fang, J., Erdjument‐Bromage, H., Warren, M., Borchers, C. H., Tempst, P., & Zhang, Y. (2005) · Nature · doi:10.1038/nature04433 · Cited by 2,171 · see citing works

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097 · see citing works

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020 · see citing works

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985 · see citing works

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes &amp; Development · doi:10.1101/gad.1110003 · Cited by 1,911 · see citing works

Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action

Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Sujuti, H., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810 · see citing works

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · see citing works

Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb

Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00506-2 · Cited by 1,211 · see citing works

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · see citing works

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,185 · see citing works

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells

Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153 · see citing works

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes &amp; Development · doi:10.1101/gad.995802 · Cited by 1,093 · see citing works

Reversal of Histone Lysine Trimethylation by the JMJD2 Family of Histone Demethylases

Whetstine, J. R., Nottke, A. C., Lan, F., Huarte, M., Smolikov, S., Chen, Z., Spooner, E., Li, E., Zhang, G., Colaiácovo, M. P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.028 · Cited by 1,046 · see citing works

Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2

Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043 · see citing works

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · see citing works

GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR

Kim, D., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 955 · see citing works

mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation

Morita, M., Gravel, S.-P., Chénard, V., Sikström, K., Zheng, L., Alain, T., Gandin, V., Avizonis, D., Arguello, M., Zakaria, C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.001 · Cited by 842 · see citing works

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 813 · see citing works

The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3

Cloos, P. A., Christensen, J., Agger, K., Maiolica, A., Rappsilber, J., Antal, T., Hansen, K. H., & Helin, K. (2006) · Nature · doi:10.1038/nature04837 · Cited by 738 · see citing works

Glutaminolysis Activates Rag-mTORC1 Signaling

Durán, R. V., Oppliger, W., Robitaille, A. M., Heiserich, L., Skendaj, R., Gottlieb, E., & Hall, M. N. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.043 · Cited by 723 · see citing works

( <i>R</i> )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703 · see citing works

mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s

Frías, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W. A., Sculley, T. B., Carr, S. A., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.001 · Cited by 690 · see citing works

The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36

Klose, R. J., Yamane, K., Bae, Y., Zhang, D., Erdjument‐Bromage, H., Tempst, P., Wong, J., & Zhang, Y. (2006) · Nature · doi:10.1038/nature04853 · Cited by 630 · see citing works

The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR

Chin, R., Fu, X., Pai, M. Y., Vergnes, L., Hwang, H., Deng, G., Diep, S., Lomenick, B., Meli, V. S., Monsalve, G. C., et al. (2014) · Nature · doi:10.1038/nature13264 · Cited by 608 · see citing works

The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4

Csibi, A., Fendt, S.-M., Li, C., Poulogiannis, G., Choo, A. Y., Chapski, D. J., Jeong, S. M., Dempsey, J. M., Parkhitko, A., Morrison, T., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.023 · Cited by 586 · see citing works

Regulation of autophagy by cytosolic acetyl-coenzyme A

Mariño, G., Pietrocola, F., Eisenberg, T., Kong, Y., Malik, S. A., Andryushkova, A., Schroeder, S., Pendl, T., Harger, A., Niso-Santano, M., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.01.016 · Cited by 500 · see citing works

Tudor, MBT and chromo domains gauge the degree of lysine methylation

Kim, J., Daniel, J. A., Espejo, A. B., Lake, A., Krishna, M., Li, X., Zhang, Y., & Bedford, M. T. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400625 · Cited by 493 · see citing works

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

Pearce, L. R., Huang, X., Boudeau, J., Pawłowski, R., Wullschleger, S., Deák, M., Ibrahim, A. F. M., Gourlay, R., Magnuson, M. A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070540 · Cited by 462 · see citing works

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

Liu, X.-Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.-A., Fontebasso, A. M., Fleming, A. J., Hadjadj, D., Schwartzentruber, J., Majewski, J., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1031-3 · Cited by 428 · see citing works

RNF8‐ and RNF168‐dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites

Mallette, F. A., Mattiroli, F., Cui, G., Young, L. C., Hendzel, M. J., Mer, G., Sixma, T. K., & Richard, S. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.47 · Cited by 358 · see citing works

Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity

Ng, S. S., Kavanagh, K. L., McDonough, M. A., Butler, D. S., Pilka, E. S., Liénard, B. M. R., Bray, J. E., Savitsky, P. A., Gileadi, O., von Delft, F., et al. (2007) · Nature · doi:10.1038/nature05971 · Cited by 329 · see citing works

DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCFβTrCP E3 Ubiquitin Ligase and Regulates Survival and Autophagy

Zhao, Y., Xiong, X., & Sun, Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.029 · Cited by 270 · see citing works

mTOR Drives Its Own Activation via SCFβTrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR

Gao, D., Inuzuka, H., Tan, M.-K. M., Fukushima, H., Locasale, J. W., Liu, P., Wan, L., Zhai, B., Chin, Y. R., Shaik, S., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.030 · Cited by 248 · see citing works

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling

Fu, X., Chin, R., Vergnes, L., Hwang, H., Deng, G., Xing, Y., Pai, M. Y., Li, S., Ta, L. H., Fazlollahi, F., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.009 · Cited by 230 · see citing works

KDM4A Lysine Demethylase Induces Site-Specific Copy Gain and Rereplication of Regions Amplified in Tumors

Black, J. C., Manning, A. L., Rechem, C. V., Kim, J., Ladd, B., Cho, J., Pineda, C. M., Murphy, N., Daniels, D. L., Montagna, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.051 · Cited by 214 · see citing works

Role of androgen receptor and associated lysine‐demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer

KAUFFMAN, E. C., Robinson, B. D., Downes, M., Powell, L. G., Lee, M. M., Scherr, D. S., Gudas, L. J., & Mongan, N. P. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20758 · Cited by 211 · see citing works

mTOR Generates an Auto-Amplification Loop by Triggering the βTrCP- and CK1α-Dependent Degradation of DEPTOR

Duan, S., Skaar, J. R., Kuchay, S., Toschi, A., Kanarek, N., Ben‐Neriah, Y., & Pagano, M. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.09.005 · Cited by 194 · see citing works

IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group

for the Children’s Oncology Group, Pollack, I. F., Hamilton, R. L., Sobol, R. W., Nikiforova, M. N., Lyons‐Weiler, M. A., LaFramboise, W. A., Burger, P. C., Brat, D. J., Rosenblum, M. K., et al. (2010) · Child s Nervous System · doi:10.1007/s00381-010-1264-1 · Cited by 185 · see citing works

Genetic profile of astrocytic and oligodendroglial gliomas

Ohgaki, H., & Kleihues, P. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-011-0029-1 · Cited by 167 · see citing works

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation

Li, S., Chou, A. P., Chen, W., Chen, R., Deng, Y., PHILLIPS, H. S., Selfridge, J. M., Zurayk, M., Lou, J. J., Everson, R. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos261 · Cited by 154 · see citing works

PGC-1α supports glutamine metabolism in breast cancer

McGuirk, S., Gravel, S., Deblois, G., Papadopoli, D. J., Faubert, B., Wegner, A., Hiller, K., Avizonis, D. Z., Akavia, U. D., Jones, R. G., et al. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-22 · Cited by 153 · see citing works

Conserved Antagonism between JMJD2A/KDM4A and HP1γ during Cell Cycle Progression

Black, J. C., Allen, A., Rechem, C. V., Forbes, E. K., Longworth, M. S., Tschöp, K., Rinehart, C. A., Quiton, J., Walsh, R. M., Smallwood, A., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.11.008 · Cited by 151 · see citing works

Diversity within the JMJD2 histone demethylase family

Shin, S., & Janknecht, R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.147 · Cited by 142 · see citing works

Noncanonical NF-κB Pathway Controls the Production of Type I Interferons in Antiviral Innate Immunity

Jin, J., Hu, H., Li, H. S., Yu, J., Xiao, Y., Brittain, G. C., Zou, Q., Cheng, X., Mallette, F. A., Watowich, S. S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.006 · Cited by 139 · see citing works

JMJD2A Promotes Cellular Transformation by Blocking Cellular Senescence through Transcriptional Repression of the Tumor Suppressor CHD5

Mallette, F. A., & Richard, S. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.033 · Cited by 119 · see citing works

SCFFbxo22-KDM4A targets methylated p53 for degradation and regulates senescence

Johmura, Y., Sun, J. M., Kitagawa, K., Nakanishi, K., Kuno, T., Naiki‐Ito, A., Sawada, Y., Miyamoto, T., Okabe, A., Aburatani, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10574 · Cited by 119 · see citing works

JMJD2A Is a Novel N-CoR-Interacting Protein and Is Involved in Repression of the Human Transcription Factor Achaete Scute-Like Homologue 2 (ASCL2/Hash2)

Zhang, D., Yoon, H., & Wong, J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.15.6404-6414.2005 · Cited by 118 · see citing works

Enabling Lead Discovery for Histone Lysine Demethylases by High-Throughput RapidFire Mass Spectrometry

Hutchinson, S., Leveridge, M. V., Heathcote, M. L., Francis, P. L., Williams, L., Gee, M., Muñoz, J. A., Leavens, B. J., Shillings, A., Jones, E. J., et al. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111416660 · Cited by 101 · see citing works

Identification and characterization of TMEM24 family genes in silico

Katoh, M., & Katoh, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.759 · Cited by 97 · see citing works

miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells

Neault, M., Mallette, F. A., & Richard, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.068 · Cited by 75 · see citing works

Glutamate dehydrogenase contributes to leucine sensing in the regulation of autophagy

Lorin, S., Tol, M. J. P. M., Bauvy, C., Strijland, A., Poüs, C., Verhoeven, A. J., Codogno, P., & Meijer, A. J. (2013) · Autophagy · doi:10.4161/auto.24083 · Cited by 73 · see citing works

The complete targeted profile of the organic acid intermediates of the citric acid cycle using a single stable isotope dilution analysis, sodium borodeuteride reduction and selected ion monitoring GC/MS

Mamer, O., Gravel, S., Choinière, L., Chénard, V., St‐Pierre, J., & Avizonis, D. Z. (2013) · Metabolomics · doi:10.1007/s11306-013-0521-1 · Cited by 52 · see citing works

Transcriptome analysis and tumor suppressor requirements of STAT5‐induced senescence

Mallette, F. A., Moiseeva, O. V., Calabrese, V., Mao, B., Gaumont‐Leclerc, M., & Ferbeyre, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05192.x · Cited by 21 · see citing works

Metabolomics for Investigating Physiological and Pathophysiological Processes

Wishart, D. S. (2019) · Physiological Reviews · doi:10.1152/physrev.00035.2018 · Cited by 1,247 · see citing works

Regulation and metabolic functions of mTORC1 and mTORC2.

Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 723 · see citing works

Navigating metabolic pathways to enhance antitumour immunity and immunotherapy

Li, X., Wenes, M., Romero, P. J., Huang, S. C., Fendt, S., & Ho, P. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 745 · see citing works

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626 · see citing works

The role of ubiquitination and deubiquitination in cancer metabolism

Sun, T., Liu, Z., & Yang, Q. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01262-x · Cited by 518 · see citing works

Coupling Krebs cycle metabolites to signalling in immunity and cancer

Ryan, D. G., Murphy, M. P., Frezza, C., Prag, H. A., Chouchani, E. T., O’Neill, L. A., & Mills, E. L. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0014-7 · Cited by 398 · see citing works

Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets

Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 348 · see citing works

Biological Role and Therapeutic Potential of IDH Mutations in Cancer

Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 334 · see citing works

Signaling Pathways Involved in the Regulation of mRNA Translation

Roux, P. P., & Topisirović, I. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00070-18 · Cited by 314 · see citing works

Marked for death: Targeting epigenetic changes in cancer

Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · see citing works

Targeting Epigenetics in Cancer

Bennett, R. L., & Licht, J. D. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 252 · see citing works

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates

Ye, D., Guan, K.-L., & Xiong, Y. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.005 · Cited by 242 · see citing works

2-Oxoglutarate-dependent dioxygenases in cancer

Losman, J.-A., Koivunen, P., & Kaelin, W. G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00303-3 · Cited by 225 · see citing works

The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism

Chang, S., Yim, S., & Park, H. (2019) · Experimental &amp; Molecular Medicine · doi:10.1038/s12276-019-0230-6 · Cited by 228 · see citing works

mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer

de la Cruz-López, K. G., Toledo-Guzmán, M. E., Sánchez, E. O., & Carrancá, A. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01373 · Cited by 215 · see citing works

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

Choe, S. E., Wang, H., Dinardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Watts, J. M., Pollyea, D. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001503 · Cited by 210 · see citing works

Emerging role of PI3K/AKT in tumor-related epigenetic regulation

Yang, Q., Jiang, W., & Hou, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.04.001 · Cited by 206 · see citing works

Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications

Wei, Q., Qian, Y., Yu, J. Q., & Wong, C. C. (2020) · Oncogene · doi:10.1038/s41388-020-01432-7 · Cited by 188 · see citing works

HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells

Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169 · see citing works

Glutaminolysis Promotes Collagen Translation and Stability via α-Ketoglutarate–mediated mTOR Activation and Proline Hydroxylation

Ge, J., Cui, H., Xie, N., Banerjee, S., Guo, S., Dubey, S., Barnes, S., & Liu, G. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0238oc · Cited by 166 · see citing works

Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK

Su, Y., Wang, T., Wu, N., Li, D., Fan, X., Xu, Z., Mishra, S. K., & Yang, M. (2019) · Aging · doi:10.18632/aging.102045 · Cited by 168 · see citing works

Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma

Wu, M., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1077 · Cited by 157 · see citing works

Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling

Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 141 · see citing works

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancerPreprint

Audet‐Walsh, É., Dufour, C. R., Yee, T., Zouanat, F. Z., Yan, M., Kalloghlian, G., Vernier, M., Caron, M., Bourque, G., Scarlata, E., et al. (2017) · Genes & Development · doi:10.1101/gad.299958.117 · Cited by 137 · see citing works

2-Hydroxyglutarate in Cancer Cells

Ježek, P. (2020) · Antioxidants &amp; Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130 · see citing works

D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization

Böttcher, M., Renner, K., Berger, R., Mentz, K., Thomas, S., Cardenas-Conejo, Z. E., Dettmer, K., Oefner, P. J., Mackensen, A., Kreutz, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445454 · Cited by 124 · see citing works

IL-37 Ameliorating Allergic Inflammation in Atopic Dermatitis Through Regulating Microbiota and AMPK-mTOR Signaling Pathway-Modulated Autophagy Mechanism

Hou, T., Sun, X., Zhu, J. F., Hon, K. E., Jiang, P., Chu, I. M., Tsang, M. S., Lam, C. W.-K., Zeng, H., & Wong, C. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00752 · Cited by 115 · see citing works

The mTORC2 signaling network: targets and cross-talks

Ragupathi, A., Kim, C., & Jacinto, E. (2024) · Biochemical Journal · doi:10.1042/bcj20220325 · Cited by 113 · see citing works

Metabolism and epigenetics at the heart of T cell function

Soriano‐Baguet, L., & Brenner, D. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.01.002 · Cited by 94 · see citing works

Signaling pathways in brain tumors and therapeutic interventions

Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 98 · see citing works

IDH-mutated gliomas promote epileptogenesis through d -2-hydroxyglutarate-dependent mTOR hyperactivation

Mortazavi, A., Fayed, I., Bachani, M., Dowdy, T., Jahanipour, J., Khan, A. U., Owotade, J., Walbridge, S., Inati, S. K., Steiner, J. P., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac003 · Cited by 92 · see citing works

The tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting mTORC1-dependent metabolic activation

Suzuki, J., Yamada, T., Inoue, K., Nabe, S., Kuwahara, M., Takemori, N., Takemori, A., Matsuda, S., Kanoh, M., Imai, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05854-6 · Cited by 87 · see citing works

DEPTOR at the Nexus of Cancer, Metabolism, and Immunity

Caron, A., Briscoe, D. M., Richard, D., & Laplante, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00064.2017 · Cited by 84 · see citing works

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells

Badur, M. G., Muthusamy, T., Parker, S. J., Ma, S., McBrayer, S. K., Cordes, T., Magaña, J. H., Guan, K., & Metallo, C. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.074 · Cited by 82 · see citing works

IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?

Kayabölen, A., Yilmaz, E., & Onder, T. B. (2021) · Biomedicines · doi:10.3390/biomedicines9070799 · Cited by 83 · see citing works

D-2-Hydroxyglutarate in Glioma Biology

Chou, F.-J., Liu, Y., Lang, F., & Yang, C. (2021) · Cells · doi:10.3390/cells10092345 · Cited by 83 · see citing works

mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics

Zhang, H., Xiao, X., Pan, Z., & Dokudovskaya, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02493-4 · Cited by 91 · see citing works

PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications

Mohamed, E., Kumar, A., Zhang, Y., Wang, A. S., Chen, K. Y., Lim, Y., Shai, A., Taylor, J. W., Clarke, J. L., Hilz, S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac064 · Cited by 82 · see citing works

The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity

Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 73 · see citing works

The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-κB pathway

Han, C., Zheng, J., Sun, L., Yang, H., Cao, Z., Zhang, X., Zheng, L. T., & Zhen, X.-C. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0225-9 · Cited by 73 · see citing works

Biology of IDH mutant cholangiocarcinoma

Wu, M., Shi, L., Merritt, J., Zhu, A. X., & Bardeesy, N. M. (2022) · Hepatology · doi:10.1002/hep.32424 · Cited by 71 · see citing works

Health benefits of late-onset metformin treatment every other week in mice

Alfaras, I., Mitchell, S. J., Mora, H., Lugo, D. R., Warren, A., Navas-Enamorado, I., Hoffmann, V., Hine, C., Mitchell, J. R., Le Couteur, D. G., et al. (2017) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-017-0018-7 · Cited by 68 · see citing works

Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities

Neitzel, C., Demuth, P., Wittmann, S., & Fahrer, J. (2020) · Cancers · doi:10.3390/cancers12071731 · Cited by 68 · see citing works

Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities

Liu, S., Cadoux-Hudson, T. A. D., & Schofield, C. J. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.06.012 · Cited by 70 · see citing works

Real-Time Monitoring of Tricarboxylic Acid Metabolites in Exhaled Breath

Rioseras, A. T., Singh, K. D., Nowak, N., Gaugg, M. T., Bruderer, T., Zenobi, R., & Sinues, P. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04600 · Cited by 65 · see citing works

SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors

Wang, X., Chen, Z., Xu, J., Tang, S., An, N., Jiang, L., Zhang, Y., Zhang, S., Zhang, Q., Shen, Y., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00650-w · Cited by 60 · see citing works

Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies

Gonsalves, W. I., Ramakrishnan, V., Hitosugi, T., Ghosh, T., Jevremovic, D., Dutta, T., Sakrikar, D., Petterson, X.-M., Wellik, L., Kumar, S. K., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.94543 · Cited by 57 · see citing works

The Acidic Brain—Glycolytic Switch in the Microenvironment of Malignant Glioma

Reuss, A. M., Groos, D., Buchfelder, M., & Savaskan, N. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115518 · Cited by 57 · see citing works

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations

Hvinden, I. C., Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100469 · Cited by 59 · see citing works

Metabolic reprogramming of pulmonary fibrosis

Li, J., Zhai, X., Sun, X., Cao, S., Yuan, Q., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1031890 · Cited by 56 · see citing works

Postoperative risk of IDH mutant glioma–associated seizures and their potential management with IDH mutant inhibitors

Drumm, M. R., Wang, W., Sears, T. K., Burdett, K. B., Javier, R. A., Cotton, K. Y., Webb, B., Byrne, K., Unruh, D. J., Thirunavu, V. M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168035 · Cited by 55 · see citing works

The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy

Wu, J., Liu, N., Chen, J., Tao, Q., Li, Q., Li, J., Chen, X., & Peng, C. (2024) · Research · doi:10.34133/research.0351 · Cited by 57 · see citing works

The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling

Yamashita, A. S., Rosa, M. D. C., Stumpo, V., Rais, R., Slusher, B. S., & Riggins, G. J. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa149 · Cited by 53 · see citing works

Metabolomics and the Multi-Omics View of Cancer

Wishart, D. S. (2022) · Metabolites · doi:10.3390/metabo12020154 · Cited by 51 · see citing works

Mitochondrial Genetic and Epigenetic Regulations in Cancer: Therapeutic Potential

Wagner, A., Kosnacova, H., Chovanec, M., & Jurkovičová, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147897 · Cited by 51 · see citing works

T cell-specific deletion of Pgam1 reveals a critical role for glycolysis in T cell responses

Toriyama, K., Kuwahara, M., Kondoh, H., Mikawa, T., Takemori, N., Konishi, A., Yorozuya, T., Yamada, T., Soga, T., Shiraishi, A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01122-w · Cited by 48 · see citing works

Omega-3 polyunsaturated fatty acids prevent obesity by improving tricarboxylic acid cycle homeostasis

Liu, R., Chen, L., Wang, Z., Zheng, X., Hou, Z., Zhao, D., Long, J., & Liu, J. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108503 · Cited by 47 · see citing works

Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis

Taha‐Mehlitz, S., Bianco, G., Coto‐Llerena, M., Kancherla, V., Bantug, G. R., Gallon, J., Ercan, C., Panebianco, F., Eppenberger‐Castori, S., von Strauss, M., et al. (2021) · Theranostics · doi:10.7150/thno.50051 · Cited by 47 · see citing works

Rescue of TCA Cycle Dysfunction for Cancer Therapy

Marquez, J. C., Flores, J., Kim, A. H., Nyamaa, B., Nguyen, A. T. T., Park, N., & Han, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122161 · Cited by 46 · see citing works

Iron Drives Anabolic Metabolism Through Active Histone Demethylation and mTORC1

Shapiro, J., Chang, H.-C., Tatekoshi, Y., Zhao, Z.-B., Waxali, Z. S., Hong, B., Chen, H., Geier, J. A., Bartom, E., Jesus, A. D., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01225-6 · Cited by 35 · see citing works

Metabolite activation of tumorigenic signaling pathways in the tumor microenvironment

Low, V., Li, Z., & Blenis, J. (2022) · Science Signaling · doi:10.1126/scisignal.abj4220 · Cited by 44 · see citing works

Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2

Liu, Y., Chou, F.-J., Lang, F., Zhang, M., Song, H., Zhang, W., Davis, D. L., Briceno, N., Zhang, Y., Cimino, P. J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3179 · Cited by 41 · see citing works

Physiological and Pathological Role of mTOR Signaling in Astrocytes

Hochmuth, L., & Hirrlinger, J. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04306-6 · Cited by 41 · see citing works

A d-2-hydroxyglutarate biosensor based on specific transcriptional regulator DhdR

Xiao, D., Zhang, W., Guo, X., Liu, Y., Hu, C., Guo, S., Kang, Z., Xu, X., Ma, C., Gao, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27357-7 · Cited by 34 · see citing works

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax

Fooks, K., Galicia-Vázquez, G., Gife, V., Schcolnik-Cabrera, A., Nouhi, Z., Poon, W. W. L., Luo, V. M., Rys, R., Aloyz, R., Orthwein, A., et al. (2022) · Journal of experimental & clinical cancer research : CR · doi:10.1186/s13046-022-02542-8 · Cited by 23 · see citing works

Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma

Bloedjes, T. A., de Wilde, G., & Guikema, J. E. J. (2021) · Cancers · doi:10.3390/cancers13030396 · Cited by 32 · see citing works

IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives

Crispo, F., Pietrafesa, M., Condelli, V., Maddalena, F., Bruno, G., Piscazzi, A., Sgambato, A., Esposito, F., & Landriscina, M. (2020) · Molecules · doi:10.3390/molecules25163754 · Cited by 32 · see citing works

Translational control in brain pathologies: biological significance and therapeutic opportunities

Delaidelli, A., Jan, A., Herms, J. W., & Sorensen, P. H. B. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01971-8 · Cited by 30 · see citing works

Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells

Chiarini, F., Evangelisti, C., Lattanzi, G., McCubrey, J. A., & Martelli, A. M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.03.013 · Cited by 31 · see citing works

2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies

Raimondi, V., Ciotti, G., Gottardi, M., & Ciccarese, F. (2022) · Biomedicines · doi:10.3390/biomedicines10061359 · Cited by 31 · see citing works

Oligodendroglioma: A Review of Management and Pathways

Zerdan, M. B., & Assi, H. I. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.722396 · Cited by 29 · see citing works

The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities

Yang, G., Li, C., Tao, F., Liu, Y., Zhu, M., Du, Y., Fei, C., She, Q., & Chen, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.12.020 · Cited by 29 · see citing works

Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- IDH1 Cholangiocarcinoma

Aguado-Fraile, E., Tassinari, A. M., Ishii, Y., Sigel, C., Lowery, M. A., Goyal, L., Gliser, C., Jiang, L., Pandya, S. S., Wu, B., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1274 · Cited by 28 · see citing works

Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients

Li, H., Shan, C., Wu, S., Cheng, B., Fan, C., Cai, L., Chen, Y., Shi, Y., Liu, K., Shao, Y. W., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.607429 · Cited by 28 · see citing works

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database

Pappula, A. L., Rasheed, S., Mirzaei, G., Petreaca, R. C., & Bouley, R. A. (2021) · Cancers · doi:10.3390/cancers13174299 · Cited by 27 · see citing works

mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma

Liu, Y., Lu, Y., Li, A., Celiku, O., Han, S., Qian, M., & Yang, C. (2020) · Cancers · doi:10.3390/cancers12040787 · Cited by 26 · see citing works

One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation

Esterhuizen, K., Lindeque, J. Z., Mason, S., van der Westhuizen, F. H., Rodenburg, R. J., de Laat, P., Smeitink, J. A. M., Janssen, M. C. H., & Louw, R. (2021) · Metabolomics · doi:10.1007/s11306-020-01769-w · Cited by 26 · see citing works

The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-mTOR signaling

Li, M., Cheng, J., Ma, Y., Guo, H., Shu, H., Huang, H., Kuang, Y.-Q., & Yang, T. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01177-z · Cited by 25 · see citing works

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells

Hujber, Z., Petővári, G., Szoboszlai, N., Dankó, T., Nagy, N., Kriston, C., Krencz, I., Paku, S., Ozohanics, O., Drahos, L., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0544-y · Cited by 25 · see citing works

Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma

Mehrjardi, N. Z., Hänggi, D., & Kahlert, U. D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03196-0 · Cited by 23 · see citing works

Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Fiehn, O., Showalter, M. R., Tooley, C. E. S., & Reproducibility Project: Cancer Biology (2016) · eLife · doi:10.7554/elife.12626 · Cited by 24 · see citing works

Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting

Pan, B., Hsu, C.-C., Wu, H., Chen, Y.-R., Zhou, X., Wang, S., Li, C., & Lin, H.-K. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01167-1 · Cited by 24 · see citing works

RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells

Zhu, S., Luo, Y., Li, K., Mei, C., Wang, Y., Jiang, L., Wang, W., Zhang, Q., Yang, W., Lang, W., et al. (2024) · Science Advances · doi:10.1126/sciadv.adi1782 · Cited by 23 · see citing works

Molecular Regulation of Cellular Senescence by MicroRNAs: Implications in Cancer and Age-Related Diseases

Neault, M., Couteau, F., Bonneau, É., Guire, V. D., & Mallette, F. A. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.04.001 · Cited by 22 · see citing works

Epilepsy in gliomas: recent insights into risk factors and molecular pathways

Rudà, R., Bruno, F., & Pellerino, A. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001214 · Cited by 22 · see citing works

Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells

Shen, X., Wu, S., Zhang, J., Li, M., Xu, F., Wang, A., Yang, L., & Zhu, G. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11250 · Cited by 22 · see citing works

Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future

Huang, W., Hao, Z., Mao, F., & Guo, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.911876 · Cited by 23 · see citing works

The Roles of IDH1 in Tumor Metabolism and Immunity

Ni, Y., Shen, P., Wang, X. T., Liu, H., Luo, H., & Han, X. (2022) · Future Oncology · doi:10.2217/fon-2022-0583 · Cited by 23 · see citing works

IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway

Zhang, L., Qi, M., Feng, T., Hu, J., Wang, L., Li, X., Gao, W. Q., Liu, H., Jiao, M., Wu, Z., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2017.12.001 · Cited by 21 · see citing works

Molecular and Metabolic Reprogramming: Pulling the Strings Toward Tumor Metastasis

Hipólito, A., Martins, F., Mendes, C., Lopes‐Coelho, F., & Serpa, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656851 · Cited by 21 · see citing works

Morin inhibits the transformation of fibroblasts towards myofibroblasts through regulating “PPAR-γ-glutaminolysis-DEPTOR” pathway in pulmonary fibrosis

Miao, Y., Geng, Y., Yang, L., Zheng, Y., Dai, Y., & Wei, Z. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108923 · Cited by 21 · see citing works

L-2hydroxyglutaric acid rewires amino acid metabolism in colorectal cancer via the mTOR-ATF4 axis

Tabata, S., Kojima, Y., Sakamoto, T., Igarashi, K., Umetsu, K., Ishikawa, T., Hirayama, A., Kajino‐Sakamoto, R., Sakamoto, N., Yasumoto, K., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02632-7 · Cited by 22 · see citing works

Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1α axis

Liu, X., Yamaguchi, K., Takane, K., Zhu, C., Hirata, M., Hikiba, Y., Maeda, S., Furukawa, Y., & Ikenoue, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257090 · Cited by 20 · see citing works

Antitumor Potential of Antiepileptic Drugs in Human Glioblastoma: Pharmacological Targets and Clinical Benefits

Stella, M., Baiardi, G., Pasquariello, S., Sacco, F., Dellacasagrande, I., Corsaro, A., Mattioli, F., & Barbieri, F. (2023) · Biomedicines · doi:10.3390/biomedicines11020582 · Cited by 20 · see citing works

Downregulation of respiratory complex I mediates major signalling changes triggered by TOR activation

Pérez-Gómez, R., Magnin, V., Mihajlović, Z., Slaninová, V., & Krejčı́, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-61244-3 · Cited by 19 · see citing works

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Showalter, M. R., Hatakeyama, J., Čajka, T., VanderVorst, K., Carraway, K. L., Fiehn, O., & Reproducibility Project: Cancer Biology (2017) · eLife · doi:10.7554/elife.26030 · Cited by 19 · see citing works

SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma

Luk, I. S. U., Bridgwater, C. M., Yu, A. Y. C., Boila, L. D., Yáñez-Bartolomé, M., Lampano, A., Hulahan, T. S., Boukhali, M., Kathiresan, M., Macarulla, T. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj7685 · Cited by 18 · see citing works

The Interplay between Dysregulated Metabolism and Epigenetics in Cancer

Bassal, M. A. (2023) · Biomolecules · doi:10.3390/biom13060944 · Cited by 19 · see citing works

Changes in Plasma Pyruvate and TCA Cycle Metabolites upon Increased Hepatic Fatty Acid Oxidation and Ketogenesis in Male Wistar Rats

Dankel, S. N., Kalleklev, T., Tungland, S. L., Stafsnes, M. H., Bruheim, P., Aloysius, T. A., Lindquist, C., Skorve, J., Nygard, O. K., Madsen, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115536 · Cited by 18 · see citing works

Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison

Nepstad, I., Hatfield, K. J., Aasebø, E., Hernandez-Valladares, M., Brenner, A. K., Bartaula-Brevik, S., Berven, F. S., Selheim, F., Skavland, J., Gjertsen, B. T., et al. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1487401 · Cited by 18 · see citing works

Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling

Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 141 · see citing works

Activation de la voie oncogénique mTOR par les formes mutées de l'isocitrate déshydrogénase 1/2 retrouvées chez les gliomes

Carbonneau, M. (2015) · doi:10.71781/27721

The common feature of cancer-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to the oncometabolite 2-hydroxyglutarate

Ward, P. S. (2013) · Scholarly Commons (University of Pennsylvania)

What a difference a hydroxyl makes: mutant IDH, (<i>R</i>)-2-hydroxyglutarate, and cancer

Losman, J.-A., & Kaelin, W. G. (2013) · Genes &amp; Development · doi:10.1101/gad.217406.113 · Cited by 570 · see citing works

The Roles of 2-Hydroxyglutarate

Du, X., & Hu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651317 · Cited by 152 · see citing works